Panacea Biotec Limited reported a consolidated net loss of ₹716 lakh for the financial year ended March 31, 2026, narrowing from a loss of ₹872 lakh in the previous year. The standalone entity reported a net loss of ₹2,988 lakh for FY26. Total consolidated income from operations rose to ₹63,977 lakh from ₹55,909 lakh in FY25. The board passed over the dividend for the financial year on equity and preference shares due to losses incurred during the year.

The board appointed Mr. Rajinder Singh Manku as an additional non-executive independent director for a term of five years effective July 1, 2026, subject to shareholder approval. The meeting was held on May 30, 2026, where the standalone and consolidated audited financial results were approved. The statutory auditors provided an unmodified opinion on the results.

Financial Performance

The company’s consolidated total income for FY26 stood at ₹65,667 lakh, compared to ₹57,975 lakh in the previous year. For the quarter ended March 31, 2026, the company reported a consolidated net loss of ₹100 lakh, while the standalone net loss was ₹18 lakh. Total comprehensive income for the consolidated entity for the year was a loss of ₹174 lakh.

Segment Performance

The Vaccines segment reported revenue of ₹41,025 lakh for FY26, while the Formulations segment recorded revenue of ₹22,952 lakh. The Vaccines segment reported a loss before tax of ₹2,684 lakh, whereas the Formulations segment reported a profit before tax of ₹1,947 lakh.

Auditor's Report and Going Concern

The statutory auditors, Suresh Surana & Associates LLP, highlighted a material uncertainty related to the company's ability to continue as a going concern due to incurred losses and negative retained earnings. The standalone retained earnings were negative to the extent of ₹21,782 lakh as on March 31, 2026. However, management prepared the financial results on a going concern basis based on future projections and confirmed orders.

Regulatory Disclosures

The company published the extract of the audited standalone and consolidated financial results for FY26 in Business Standard and Desh Sewak on June 01, 2026. The filing was made in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Panacea Biotec Pharma Limited (PBPL), a material wholly owned subsidiary of panacea biotec , has approved the appointment of Mr. Krishan Kumar Jalan and the re-appointment of Mrs. Manjula Upadhyay as non-executive independent directors. The decisions were made during a board meeting held on May 29, 2026. Both appointments are subject to approval from the shareholders of the subsidiary.

Mr. Krishan Kumar Jalan has been appointed as an additional director for a period commencing July 01, 2026, until February 13, 2030. His tenure aligns with his current term as an independent director at Panacea Biotec. Mrs. Manjula Upadhyay has been re-appointed for a term of five consecutive years, effective from July 23, 2026, to July 22, 2031. Neither director is liable to retire by rotation.

The board disclosed that both appointees bring extensive experience to their roles. Mr. Jalan is a retired IAS officer with over 35 years of experience in the Indian Administrative Service, having served in senior positions such as Additional Chief Secretary and Principal Secretary in the Haryana Government. Mrs. Upadhyay is a practicing lawyer with approximately 37 years of experience, specializing in labour laws, and currently serves as the Managing Partner of MR Lex Corp LLP.

The filings confirm that neither director is related to any existing director on the board. Furthermore, both individuals are not debarred from holding the office of director by any SEBI order or other regulatory authority. The disclosures were made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Details

The appointments are intended to strengthen the decision-making processes and ensure adherence to ethical practices within PBPL's board.